Flyer Biosimilars

4 Market for biosimilars The market for biologics - and thus also for biosimilars, bioidenticals and biobetters - has be- en growing for years. Gross sales for biologics have doubled in the last 10 years, and 21.5% of total SHI gross sales for finished drugs were already attributable to this group in 2016. Substitution by biosimilars offers major savings potential for the SHI system. In 2016 alone, the SHI saved 77 million euros with the help of biosimilars. With a consistent switch from bi- ologicals to biosimilar products, a further 214 million euros could be saved. On average, bio- similars are about a quarter cheaper than their originals . In view of the numerous patent expirations of biological drugs that are due in the next few years, many biosimilars will enter the German market. As a result, discounts will also continue to rise. Sales of the top 11 biosimilars in the German market reached a combined total of more than 370 million euros in 2017. Etanercept and also infliximab will soon exceed the EUR 100 million threshold. In the next few years, biosimilar sales will reach the EUR 1 billion threshold . For payers, the market segment of biosimilars and in particular the sub - segment of bioiden- ticals - due to the easier interchangeability - is a highly attractive market to achieve relevant savings in drug expenditures. The GSAV points the way forward, as the G - BA will clearly define the interchangeability of biosimilars in the future. Biosimilars Turnover 2017 (ApU) Etanercept 139.949.971 Infliximab 97.716.273 Epoetin alfa 33.141.818 Filgrastim 26.504.182 Somatropin 25.914.160 Epoetin zeta 22.114.035 Insulin glargin 16.108.615 Follitropin alfa 6.236.403 Rituximab 2.132.013 Enoxaparin 1.000.421 Insulin Lispro 41.160 collectively 370.859.051